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ABSTRACT  1 
Objectives. Our aims were (i) to describe trends in the epidemiology of Healthcare-associated 2 
Infections (HAIs) in paediatric/neonatal ICUs and (ii) to evaluate risk factors and impact of 3 
Multidrug-Resistance (MDR) in children admitted to ICUs. 4 
Design. Multicentre, retrospective, cohort study with a nested case-control study conducted 5 
between January 2010 and December 2014. 6 
Setting. Three tertiary-care paediatric hospitals in Italy and Brazil with a total of 97 ICU beds.  7 
Patients. Inclusion criteria were (i) admission to ICU during the study period (ii) age at onset <18 8 
years and (iii) microbiologically-confirmed HAI. 9 
Results. 538 HAIs in 454 children were included. 93.3% of patients had comorbidities. Bloodstream 10 
infections (BSIs) were the leading pattern (45.4%). The cumulative incidence of HAI was 3.6/100 11 
ICU-admission and the crude 30-day fatality rate was 5.7/1,000-admission. The most frequently 12 
isolated pathogens were Enterobacteriaceae, followed by Pseudomonas aeruginosa and 13 
Staphylococcus aureus. 44% of isolates were MDR. Two multivariate logistic regressions were 14 
performed. Factors independently associated with an MDR-HAI were Country, previous antibiotics, 15 
transplantation, major surgery, and colonisation by an MDR strain. Factors independently 16 
associated with 30-day case-fatality were Country, previous transplantation, fungal infection, BSI, 17 
LRTI, and infection caused by MDR strains.  18 
Conclusions. Infection control and prevention should be a primary focus to limit the spread of 19 
MDR strains and improve the outcome of hospitalised patients. Targeted surveillance programmes 20 
collecting neonatal and paediatric HAI/BSI data and outcomes would allow global benchmarking 21 
between centres. The next step is to identify simple methods to monitor key HAIs and integrate 22 
these into affordable intervention programmes.  23 
 4 
 
INTRODUCTION 1 
 2 
Healthcare-associated infections (HAIs) are one of the most frequent adverse event affecting 3 
children admitted to Intensive Care Units (ICUs).1, 2 Exposure to invasive devices and procedures, 4 
immune suppression, and underlying conditions are considered as main determinants of patients’ 5 
increased susceptibility.3, 4 The impact of multidrug-resistant (MDR) organisms in paediatrics is 6 
increasing globally.5-7 It is assumed that infections caused by MDR bacteria will have a worse 7 
prognosis because of the delay in the administration of appropriate therapy. However, it is difficult 8 
to estimate the clinical impact of MDR-HAI in children. 9 
Previous literature has showed conflicting results about the impact of different underlying risk 10 
factors on clinical outcome of patients with HAI admitted to ICUs. There is no clear independent 11 
correlation between antimicrobial resistance (AMR) and patients’ mortality.8-11  12 
Clarifying the relationship between patient risk factors and paediatric HAI mortality could allow 13 
improved targeting of interventions on the patients most at risk of adverse outcome. The aims of 14 
this study were (i) to describe trends in the epidemiology of HAIs in Italian and Brazilian paediatric 15 
ICUs over a five-year period and (ii) to evaluate patient risk factors and clinical impact of MDR-HAI 16 
in children admitted to ICUs. 17 
 18 
MATERIALS AND METHODS 19 
 20 
Study design and setting  21 
 5 
 
We conducted a multicentre, retrospective, cohort study with a nested case-control study in one 1 
paediatric hospitals in Italy and two in Brazil. These countries were chosen because of the high 2 
rates of AMR identified. The Bambino Gesù Children’s Hospital (Rome, Italy) is a 607-bed 3 
paediatric tertiary-care centre, including one neonatal (NICU), three paediatric (PICU) and one 4 
cardiac intensive care unit (CICU) (47 ICU-bed). The Prontobaby Hospital da Criança (Rio de 5 
Janeiro, Brazil) is a 135-bed private service including NICU and PICU (45 ICU-bed). The Centro 6 
Pediátrico da Lagoa (Rio de Janeiro, Brazil) is a 39-bed private service including an 11-bed PICU.  7 
The study was conducted between the 1st January 2010 and the 31st December 2014. During this 8 
period, ongoing prospective surveillance of HAIs was conducted in all the participating ICUs. 9 
Patients with a microbiologically-confirmed diagnosis of HAI were retrieved from this data source. 10 
Inclusion criteria were (i) admission to ICU during the study period (ii) age at onset <18 years and 11 
(iii) diagnosis of microbiologically-confirmed HAI. Polymicrobial infections were included if criteria 12 
for HAI were fulfilled. Episodes with a positive isolate from the same patient for the same 13 
pathogen within 4 weeks of the first one were excluded.  14 
  15 
Definitions 16 
The study was conducted using CDC HAI case definitions, with only those infections presenting and 17 
identified >48 hours after admission to ICU considered as ICU-acquired and included.12  18 
The multidrug-resistance (MDR) of the isolates was defined according to Magiorakos A-P et al.13 19 
Coagulase-negative staphylococci (CoNS) were considered as MDR if resistant to ≥3 different 20 
antibiotics classes including oxacillin, aminoglycosides, trimethoprim-sulfamethoxazole, 21 
clindamycin and quinolones.14 Isolates that did not meet MDR definition were classified as 22 
susceptible. Patients with polymicrobial infection with mixed MDR and non-MDR isolates were 23 
 6 
 
classified as MDR. Cases were defined as patients with HAI due to MDR isolates. Controls were 1 
defined as patients with HAIs caused by non-MDR.  2 
 3 
Microbiological methods 4 
In Italy, isolation and identification of microorganisms were made with accredited routine 5 
laboratory methods (Vitek® 128 2, bioMérieux, Durham, NC or Phoenix, BD Diagnostics). The CLSI 6 
criteria were used for antibiotic susceptibility testing (AST) from 2010 to 2011 whereas from 2012 7 
the EUCAST breakpoints have been introduced in the Hospital’s practice.  8 
In Brazil, isolation of microbiological species was done by semi-quantitative process (Auto-Scan 4- 9 
SIEMENS). AST were done by disk-diffusion according to CLSI recommendations until 2013 and to 10 
EUCAST from 2014. 11 
Prior colonisation with MDR strains was assessed by stool culture/rectal swab. 12 
 13 
Data source and statistical analysis 14 
We considered the cohort of patients admitted to ICU to estimate HAI cumulative incidence (HAI 15 
episodes/100 ICU-admission), rate of infections (HAI episodes/1,000 ICU-day), and mortality rate 16 
at 7-and 30-day of HAI onset (deaths among patients with at least one HAI episode/1,000 ICU-17 
admission). For all HAI episodes we collected information about possible risk factors, including 18 
demographic, clinical and microbiological variables from inpatient clinical and laboratory records. 19 
We then compared cases versus control to evaluate determinants for acquisition of HAI due to MDR, 20 
compared to non-MDR HAI. Predictors of 30-day HAI case-fatality rate was estimated by 21 
comparing survivors versus non survivors.  22 
 7 
 
Categorical variables were summarized by absolute frequencies and percentages, and continuous 1 
variables by median and interquartile range (IQR). 2 
To determine statistical differences between groups, the Chi square test or Fischer’s exact test 3 
were used for categorical variables, while the t-test or Mann-Whitney test were used for 4 
continuous variables.  5 
Two multivariate logistic regression models were developed to assess independent predictors of: 6 
1) acquisition of MDR-HAI compared to non-MDR-HAI, and 2) 30-day HAI case-fatality rate.  7 
Variables for which the p-value was <0.20 in univariate analyses were included in the multivariate 8 
models. Final models were computed with a stepwise backward procedure (likelihood ratio test 9 
p<0.05).   10 
All statistical analyses were performed using STATA, Statistical Software: Release 13. College 11 
Station, Tx: StataCorp 2013. 12 
 13 
Ethics 14 
The study was approved by the Ethical Committee of all institutions with a waiver of informed 15 
consent. 16 
 17 
RESULTS 18 
 19 
Demographic and clinical data 20 
 8 
 
During the study period 14,924 children were admitted to one of the ICUs for a total of 148,243 1 
ICU days. Overall, 538 HAI episodes in 454 children, fulfilling the inclusion criteria, were identified 2 
and included in the analysis.  3 
Characteristics of episodes of HAI are summarised in Table 1. Bloodstream infections (BSIs) were 4 
the leading pattern accounting for 244 episodes (45.4%), followed by lower respiratory tract 5 
infections (LRTIs) with 149 (27.8%) and urinary tract infections (UTIs) with 85 episodes (15.8%). 6 
The median age of patients at HAI onset was 7.8 months (IQR 2.1-26.2 months). 93.3% of HAI 7 
cases affected children with comorbidities. The median length of stay (LOS) in ICU was 67 days 8 
(IQR 31-127 days) whereas the median time between ICU admission and onset of HAI was 24 days 9 
(IQR 11-58 days).  10 
Overall, 478 out of the 538 HAIs (88.8%) were diagnosed in patients with an invasive device in situ. 11 
In 443 of them (82.3%), the device had been in place for more than 48 hours before the infection. 12 
Among BSIs, 195/244 (79.9%) interested children with a Central Venous Catheter (CVC) in situ 13 
when diagnosed (179 (73.4%) of them for >48 hours). 120 out of 149 (80.5%) LRTIs were in 14 
children mechanically-ventilated (100 (67.1%) of them for >48 hours). Among UTIs, 38/85 were in 15 
children who had a Urinary Catheter (28 (32.9%) of them for >48 hours). 16 
In 318 out of 538 episodes (59.1%), children were already on antibiotics when diagnosed with a 17 
HAI (141 (44.3%) were receiving monotherapy, 130 (40.9%) were on two, and 47 (14.8%) on three 18 
antibiotics).  19 
The cumulative incidence of HAI was 3.6/100 ICU-admission whereas the rate of infections was 20 
3.6/1,000 ICU-day. No significant trends in HAI incidence and rate were identified over the five-21 
year period. The mortality rate was 2.3/1,000-admission for 7-day and 5.7/1,000-admission for 30-22 
day mortality rate. HAI case-fatality rate at 30 days was 18.7% (85/454).   23 
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 1 
Microbiological data 2 
A total of 573 microorganisms were isolated (Table 2). Among them, 317/573 were Gram-negative 3 
bacteria (55%), 184/573 were Gram-positive bacteria (32%), and 40/573 were Fungi (7%). The 4 
most frequently isolated pathogens were Enterobacteriaceae (30.9%), followed by Pseudomonas 5 
aeruginosa (19.2%) and Staphylococcus aureus (11.0%). The percentage of MDR isolates was 44%. 6 
Based on the susceptibility profile, 79/175 (45%) of the Enterobacteriaceae were ESBL-positive. 7 
Culture-confirmed carbapenem resistance was reported in 3/175 (2%) of the Enterobacteriaceae 8 
(CRE), 46/110 (42%) of P. aeruginosa and 6/10 of Acinetobacter baumannii. Among Gram-9 
positives, 35/63 (56%) of S. aureus were methicillin-resistant (MRSA) whereas no vancomycin-10 
resistant Enterococcus spp (VRE) was isolated. 76 Coagulase-negative Staphylococci (CoNS) were 11 
isolated, 47 of which were classified as MDR (62%). Overall, 40 cultures were positive for Candida 12 
spp, all of them fully sensitive.  13 
 14 
Determinants of HAI due to MDR and 30-day case-fatality rate  15 
Out of a total of 538 episodes, 241 were due to MDR isolates, and 297 to non-MDR isolates, with 16 
no statistically significant differences in cumulative incidence (1.61 episodes/100 ICU-admissions 17 
vs 1.99/100; p=0.995). 30-day case-fatality rate was also similar in MDR-HAI episodes compared to 18 
non-MDR episodes (19.1% vs 13.1%; p=0.06).  19 
In the univariate analysis, risk factors significantly associated with HAI caused by MDR isolates 20 
compared to non-MDR isolates were country (Brazil), antibiotic use in the month before HAI, 21 
minor surgery in the six months before HAI, and previous colonisation by a MDR strain (Table 3).  22 
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In the multivariate analysis, factors independently associated with an MDR-HAI were country 1 
(Brazil), antibiotic use in the month before HAI, previous transplantation, major surgery in the six 2 
months before HAI, and previous colonisation by an MDR strain (Table 3).  3 
Risk factors associated with 30-day case-fatality are summarised in Table 4. In the univariate 4 
analysis, factors significantly associated with 30 day case-fatality were country (Brazil), 5 
prematurity, type of HAI, and microorganism category. In the multivariate multilevel analysis, 6 
factors independently associated with 30-day case-fatality were previous transplantation, BSI, 7 
LRTI, infection caused by Fungi compared to Gram-positive bacteria, and infection caused by an 8 
MDR strain. 2-5 years age group resulted as a protective factor compared to 0-28 days age group.   9 
 10 
DISCUSSION 11 
 12 
We reported a five-year experience of microbiologically-confirmed HAIs in eight ICUs at three 13 
Children’s Hospitals in Italy and Brazil.  Our study involved nearly 15,000 patients admitted 14 
between 2010 and 2014, and data on 538 HAIs were included. This cohort was larger compared to 15 
previous studies published in paediatrics. We documented a HAI incidence of 3.6% and an 16 
infection rate of 3.6/1,000 ICU days. Compared to previous reports, our rates were lower than 17 
expected, since the incidence of HAIs has been previously reported as between 7 and 12% in 18 
paediatric and between 15 and 20% in neonatal ICUs.4, 6, 15-18 The vast majority of children in our 19 
cohort had an underlying disease (93.3%), proportion quite similar to previous data in paediatric 20 
ICUs.19 21 
Consistent with previous studies, BSIs represented the leading cause of paediatric HAIs, followed 22 
by LRTIs and UTIs.6, 16-18, 20 These findings underline how children differ from adults in HAI 23 
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distribution, emphasising the need to target interventions focused on BSI prevention in neonates 1 
and children.9  2 
Of the isolated pathogens, 55% were Gram-negatives, 32% were Gram-positives and 7% were 3 
Fungi. This distribution is consistent with previous studies, conducted both in adults and children, 4 
showing that in ICU the majority of HAIs is due to Gram-negative bacteria, with 5 
Enterobacteriaceae counting for 25-30% of all isolates.4  6 
In our cohort, nearly half of the grown organisms were classified as MDR. Among 7 
Enterobacteriaceae, 45% of the isolates were ESBL-positive. This proportion was high compared to 8 
previous reports in hospitalised children.21, 22 However, this could have been over represented, 9 
since our definition was only based on susceptibility profile. Culture-confirmed carbapenem 10 
resistance was reported in only 2% of Enterobacteriaceae in our cohort. Infections due to 11 
Carbapenem-resistant Enterobacteriaceae (CRE) in adult populations have been associated with 12 
mortality rates as high as 40%.23 CRE infections are still relatively uncommon in children, with 13 
prevalence being reported less than 1% and mortality rate lower compared to adults.24  14 
In the multivariate analysis, previous colonisation by an MDR pathogen was independently 15 
associated with an MDR-HAI. Children have been proved to show particularly high colonisation 16 
rates, representing a reservoir from which bacteria can spread.25 However, the actual mechanisms 17 
leading from colonisation to infection are still debated and little surveillance data have been 18 
published so far on resistant bacteria causing invasive disease in children.  19 
One of our aims was to evaluate the impact of different patient-level risk factors on ICU-mortality. 20 
In our cohort, 30-day fatality rate for children with HAIs was 5.7/1,000-admission. This proportion 21 
was comparable to previous reports in paediatric ICUs,4 but lower compared to adults.26 In the 22 
multivariate analysis, factors independently associated with 30-day HAI case-fatality were BSI, LRTI 23 
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and infection caused by an MDR strain. Many studies have so far failed to demonstrate a clear 1 
relationship between antimicrobial resistance and mortality.8, 10, 11, 27 A possible explanation is that 2 
the currently used definitions for MDR bacteria may not be directly applicable in clinical care, as 3 
they do not take into account infection type, age or risk-adjustment.13  4 
The other factor independently associated with mortality was type of infection. In our cohort, 5 
children with BSI and LRTI had a respective risk of death 4.0 and 2.9 times higher than children 6 
with other HAIs. This finding is consistent with previous studies.4, 6, 16  7 
This study has some limitations. Children admitted to ICU are a highly heterogeneous population, 8 
characterised by different medical/surgical underlying diseases. This very variable case-mix could 9 
have influenced the analysis and misrepresented the impact of different risk factors on the 10 
outcomes. We assessed risk factors with a retrospective nested case-control study design; the 11 
independent role of determinants of HAI due to MDR and of case-fatality were assessed by logistic 12 
regression analysis. Other approaches, including multistate regression analysis, could be adopted 13 
to investigate multiple events associated with HAI, such as excess length of hospital-stay and 14 
mortality.28 Our multicentre study was conducted in two Countries; differences in population 15 
demographic, organization of care, and laboratory technics for confirming HAIs and diagnosing 16 
MDR may have influenced our results. Further studies should be conducted in multiple Countries 17 
to better address geographical variability. To this regard, multilevel regression analysis could be a 18 
useful tool to simultaneously investigate how population-level and individual-level factors 19 
contribute to disease outcomes.29  20 
Education of healthcare personnel about intravascular catheter use and procedures in ICUs have 21 
proved to be effective measures to reduce the rate of central line-associated BSIs (CLABSIs) in 22 
paediatric intensive care.30 Facility data submission mandates at national and international level 23 
 13 
 
demonstrated to improve CLABSI prevention and reduce CLABSI rates in hospitalised children.31 1 
Targeted surveillance programmes collecting neonatal and paediatric HAI/BSI data and clinical 2 
outcomes may be useful to allow global benchmarking between centres. However, the data 3 
collected for this study are just too labour intensive for routine use, especially in the low-middle 4 
income countries setting. Web-based Point Prevalence Surveys (PPSs) seem to be an effective tool 5 
to allow simple-to-collect data to be used to set benchmark and monitor interventions. The Global 6 
Antimicrobial Resistance, Prescribing, and Efficacy among Neonates and Children (GARPEC) 7 
Project,32 the repeated PPSs of HAIs and antimicrobial use in European hospitals conducted by the 8 
ECDC,33 or the International Nosocomial Infection Control Consortium (INICC)34 represent good 9 
examples of international initiatives aiming at reducing HAIs burden and their attributable 10 
mortality. The next step is to identify simple methods to monitor key HAIs and integrate these into 11 
affordable intervention programmes.   12 
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Table 1: Characteristics of episodes of HAI included in the study  1 
Variable Italy (%) Brazil (%) Total (%) p 
Total number of episodes 335  203 538  
Gender    0.831 
M 180(53.7) 111(54.7) 291(54.1)  
F 155(46.3) 92(45.3) 247(45.9)  
Median age in months (range IQR) 5.3(1.8-12.8) 14.9(4.0-49.7) 7.8(2.1-26.2) 0.001 
Age group    0.001 
0-28 days 51(15.2) 17(8.4) 68(12.6)  
29 days-3 months 74(22.1) 23(11.3) 97(18.0)  
3 months-2 years 151(45.1) 73(36.0) 224(41.6)  
2-5 years 22(6.6) 39(19.2) 61(11.3)  
>5 years 37(11.0) 51(25.1) 88(16.4)  
Underlying disease    0.001 
No 11(3.3) 25(12.3) 36(6.7)  
Yes 324(96.7) 178(87.7) 502(93.3)  
Admission ward     0.001 
NICUa 84(25.1) 30(14.8) 114(21.2)  
PICUb 96(28.7) 173(85.2) 269(50.0)  
CICUc 155(46.3) 0(-) 155(28.8)  
Median length of stay (LOS) in ICU     
ICU-days (IQR) 73(33-135) 55(26-124) 67(31-127) 0.085 
LOS pre-HAId (IQR) 24(10-55) 26(13-67) 24(11-58) 0.186 
 21 
 
HAI distribution    0.033 
Bloodstream infection 159(47.6) 85(41.9) 244(45.4)  
Lower respiratory tract infectione 88(26.4) 61(30.1) 149(27.8)  
Urinary tract infection 51(15.3) 34(16.8) 85(15.8)  
Surgical site infection 25(7.5) 7(3.5) 32(6.0)  
Other infections 11(3.3) 16(7.9) 27(5.0)  
Susceptibility of the isolate    0.001 
MDRf 119(35.5) 122(60.1) 241(44.8)  
non-MDR 216(64.5) 81(39.9) 297(55.2)  
Mortality     
7-day mortality 15(4.8) 19(10.7) 34(7.0) 0.014 
30-day mortality 25(7.8) 26(14.1) 51(10.1) 0.024 
aNICU: Neonatal intensive Care Unit; bPICU: Paediatric Intensive Care Unit; cCICU: Cardiac Intensive 1 
Care Unit; dHAI: Healthcare-associated Infections; eIncluding Pneumonia; fMDR: Multidrug-2 
Resistant  3 
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Table 2: Distribution and resistance of isolates by type of Healthcare-associated Infection 1 
Pathogen 
Bloodstream 
infection 
Lower Respiratory 
Tract Infectiona 
Urinary Tract 
Infection 
Surgical Site 
Infection 
Other 
Total isolates 
252 164 94 35 27 
n 
n 
MDRb 
% n 
n 
MDR 
% n 
n 
MDR 
% n 
n 
MDR 
% n 
n 
MDR 
% 
Total Gram 
positives 
110 52 47.3 31 19 61.3 13 3 23.1 16 9 56.3 14 9 64.3 
Total Gram 
negatives 
107 44 41.1 115 52 45.2 66 35 53 16 8 50 12 9 75 
Staphylococcus 
aureus   
25 14 56 28 17 60.7 1 0 - 7 3 42.9 2 2 100 
CoNSc   59 33 55.9 3 2 66.7 0 - - 7 5 71.4 7 6 85.7 
Klebsiella 
pneumoniae 
31 11 35.5 17 8 45.1 17 13 46.5 4 4 100 2 2 100 
Escherichia coli 10 3 30 9 3 33.3 18 8 44.4 1 0 - 1 1 100 
Pseudomonas 
aeruginosa 
27 13 48.1 57 23 40.4 19 9 47.4 6 3 50 1 0 - 
Serratia 
marcescens 
9 1 11.1 3 0 - 4 1 25 0 - - 1 1 100 
Stenotrophomonas 
maltophilia 
4 4 100 14 14 100 1 1 100 0 - - 0 - - 
Enterobacter spp 16 9 56.3 7 5 71.4 5 3 60 2 1 50 5 4 80 
Acinetobacter spp 3 2 66.7 7 3 42.9 1 1 100 1 1 100 1 1 100 
Enterococcus spp   25 5 20 0 - - 14 5 35.7 4 1 25 3 1 33.3 
Candida spp   27 0 - 5 0 - 7 0 - 0 - - 1 0 - 
Other Gram-
positives 
3 0 - 2 0 - 0 - - 0 - - 2 0 - 
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Other Gram-
negativesd 
13 5 38.5 12 6 50 7 2 28.6 3 0 - 1 0 - 
aIncluding Pneumonia; bMDR: Multidrug-Resistant; cCoNS: Coagulase-negative staphylococci; d1 1 
missing case   2 
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Table 3: Univariate and multivariate regression analysis of the impact of cohort characteristics 1 
on Healthcare-associated Infections caused by Multidrug-Resistant isolates 2 
Variable 
MDRa 
(n=241) 
non-MDR 
(n=297) 
p 
Crude 
OR 
(95%CI) p 
Adj 
OR 
(95%CI) p 
Country (%)   0.001       
Italy 119(35.5) 216(64.5)  1   1   
Brazil 122(60.1) 81(39.9)  2.73 (1.91-3.92) 0.001 3.11 (1.86-5.20) <0.001 
Age group (%)   0.070    N.I.b    
0-28 days 25(36.8) 43(63.2)  1      
29 days-3 months 40(41.2) 57(58.8)  1.21 (0.64-2.28) 0.563    
3 months-2 years 95(42.4) 129(57.6)  1.27 (0.72-2.22) 0.408    
2-5 years 35(57.4) 26(42.6)  2.32 (1.14-4.70) 0.020    
>5 years 46(52.3) 42(47.7)  1.88 (0.99-3.59) 0.055    
Male gender (%) 136(46.7) 155(53.3) 0.326 1.19 (0.84-1.67) 0.326    
Underlying conditions (%)   0.319       
No 19(52.8) 17(47.2)  1      
Yes 222(44.2) 280(55.8)  0.71 (0.36-1.40) 0.321    
Risk category (%)   0.212       
Surgery 72(38.3) 116(61.7)  1   1   
Immunodeficiency 6(40.0) 9(60.0)  1.07 (0.37-3.14) 0.896 1.51 (0.46-4.96) 0.500 
Transplantation 8(66.7) 4(33.3)  3.22 (0.94-11.09) 0.063 4.17 (1.12-15.61) 0.034 
Cancer 10(62.5) 6(37.5)  2.69 (0.94-7.70) 0.066 1.17 (0.37-3.66) 0.790 
Renal failure 5(45.5) 6(54.6)  1.34 (0.40-4.56) 0.637 0.89 (0.22-3.63) 0.874 
Prematurity 17(44.7) 21(55.3)  1.30 (0.65-2.63) 0.459 2.25 (0.96-5.31) 0.063 
Other 102(46.4) 118(53.6)  1.39 (0.94-2.07) 0.101 1.41 (0.82-2.43) 0.211 
AB use in the month before 
HAIc (%) 
  0.001       
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No 20(27.8) 52(72.2)  1   1   
Yes 217(48.2) 233(51.8)  2.42 (1.40-4.19) 0.002 2.10 (1.14-3.88) 0.017 
Type of AB (%)          
Penicillin/Ampicillin 7(36.8) 12(63.2) 0.442 1.52 (0.52-4.40) 0.443    
Combination of penicillin, 
incl. beta-lactamase 
inhibitor 
15(41.7) 21(58.3) 0.146 1.86 (0.80-4.30) 0.148 N.I.   
Cephalosporin 2nd 23(32.9) 47(67.1) 0.510 1.30 (0.63-2.67) 0.474    
Cephalosporin 3rd 21(53.9) 18(46.2) 0.007 3.03 (1.34-6.84) 0.008 1.85 (0.90-3.81) 0.093 
Carbapenem not combined 
with enzyme 
48(57.1) 36(42.9) 0.001 3.47 (1.77-6.79) 0.001 1.60 (0.93-2.66) 0.093 
Combination of 
sulfonamised/trimethoprim 
2(40.0) 3(60.0) 0.620 1.73 (0.27-11.15) 0.563    
Macrolide 7(58.3) 5(41.7) 0.048 3.64 (1.03-12.81) 0.044 N.I.   
Aminoglycoside 15(44.1) 19(55.9) 0.095 2.05 (0.88-4.81) 0.098 N.I.   
Quinolone 24(50.0) 24(50.0) 0.023 2.60 (1.21-5.59) 0.014 N.I.   
Glycopeptide 32(48.5) 34(51.5) 0.012 2.45 (1.21-4.96) 0.013 N.I.   
Surgery in the previous 6 
months (%) 
  0.063       
No 91(43.5) 118(56.5)  1   1   
Minor 40(58.0) 29(42.0)  1.80 (1.04-3.13) 0.036 1.81 (0.98-3.33) 0.058 
Major 110(42.5) 149(57.5)  0.97 (0.68-1.39) 0.851 1.99 (1.10-3.58) 0.022 
Invasive devices (%)   0.833       
No 18(43.9) 23(56.1)  1      
Yes 218(45.6) 260(54.4)  1.01 (0.54-1.91) 0.963    
Previous colonisation by 
MDR (%) 
  0.001       
No 139(38.7) 220(61.3)  1   1   
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Yes 87(63.0) 51(37.0)  2.70 (1.80-4.05) 0.001 1.72 (1.08-2.76) 0.023 
 aMDR: Multidrug-Resistant; bNot included in the final model;  cHAI: Healthcare-associated 1 
Infection   2 
 27 
 
Table 4: Univariate and multivariate regression analysis of the impact of cohort characteristics 1 
on Mortality 2 
Variable 
Survived 
(n=453) 
Non-
survived 
(n=85) 
p 
Crude 
OR 
(95%CI) p 
Adj 
OR 
(95%CI) p 
Country (%)   0.002       
Italy 295(88.1) 40(11.9)  1   1   
Brazil 158(77.8) 45(22.2)  2.10 (1.32-3.35) 0.002 3.58 (1.96-6.52) <0.001 
Age group (%)   0.187       
0-28 days 51(75.0) 17(25.0)  1   1   
29 days-3 months 81(83.5) 16(16.5)  0.59 (0.28-1.28) 0.181 0.59 (0.25-1.38) 0.226 
3 months-2 years 195(87.0) 29(13.0)  0.45 (0.23-0.87) 0.019 0.52 (0.23-1.17) 0.112 
2-5 years 53(86.9) 8(13.1)  0.45 (0.18-1.14) 0.093 0.32 (0.11-0.95) 0.039 
>5 years 73(83.0) 15(17.1)  0.62 (0.28-1.35) 0.225 0.51 (0.19-1.37) 0.181 
Male gender (%) 245(84.2) 46(15.8) 0.995 1.00 (0.63-1.59) 0.995    
Underlying  
conditions (%) 
  0.635       
No 32(88.9) 4(11.1)  1      
Yes 421(83.9) 81(16.1)  1.54 (0.53-4.47) 0.428    
Risk category (%)   0.120       
Surgery 161(85.6) 27(14.4)  1   1   
Immunodeficiency 11(73.3) 4(26.7)  2.17 (0.64-7.31) 0.212 2.00 (0.52-7.77) 0.315 
Transplantation 8(66.7) 4(33.3)  2.99 (0.84-10.59) 0.091 5.98 (1.38-25.94) 0.017 
Cancer 13(81.3) 3(18.8)  1.38 (0.37-5.15) 0.635 0.96 (0.21-4.33) 0.958 
Renal failure 10(90.9) 1(9.1)  0.60 (0.07-4.85) 0.629 0.38 (0.04-3.51) 0.395 
Prematurity 27(71.0) 11(29.0)  2.43 (1.07-5.47) 0.032 1.70 (0.67-4.28) 0.262 
Other 188(85.5) 32(14.6)  1.01 (0.58-1.77) 0.958 0.85 (0.44-1.63) 0.616 
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Previous colonisation 
by MDRa (%) 
  0.401       
No 305(85.0) 54(15.0)  1      
Yes 113(81.9) 25(18.1)  1.25 (0.74-2.10) 0.402    
Median ICU-stay pre-
HAIb (IQR) 
24.0 (11-59) 24.0 (13-51) 0.912 1.00 (0.99-1.00) 0.867    
Type of HAI   0.001       
Urinary tract infection 79(92.9) 6(7.1)  1   1   
Bloodstream infection 193(79.1) 51(20.9)  3.48 (1.43-8.43) 0.006 4.01 (1.50-10.61) 0.005 
Lower respiratory tract 
infectionc 
123(82.6) 26(17.5)  2.78 (1.10-7.07) 0.031 2.93 (1.08-8.00) 0.036 
Surgical site infection 32(100.0) 0(-)  1.00 - - 1.00 - - 
Other infections 25(92.6) 2(7.4)  1.05 (0.20-5.55) 0.951 0.88 (0.15-5.00) 0.881 
Organisms   0.031       
Gram-positive 161(87.5) 23(12.5)  1   1   
Gram-negative 266(83.9) 51(16.1)  1.34 (0.79-2.28) 0.276 1.51 (0.83-2.75) 0.182 
Fungi 26(70.3) 11(29.7)  2.96 (1.29-6.79) 0.010 4.93 (1.88-12.90) 0.001 
Susceptibility   0.060       
non-MDR 258(86.9) 39(13.1)  1   1   
MDR 195(80.9) 46(19.1)  1.56 (0.98-2.49) 0.061 1.85 (1.06-3.22) 0.030 
aMDR: Multidrug-Resistant;  bHAI: Healthcare-associated Infection;  cIncluding Pneumonia 1 
